Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Executive Vice President | May 07, 2022 | May 10, 2022 |
| CorMedix Inc.CRMD · Entity 5280 | Director · Chief Executive Officer | February 04, 2026 | February 07, 2026 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date May 07, 2022 · Filed May 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 327,194 |
Ending reported balance
After 2022-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-07 · Exercise / conversion · Acquired 4,442 · Balance 328,756 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2022-05-07 · Tax withholding · Disposed 1,562 · Balance 327,194 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-07 · Exercise / conversion · Disposed 4,442 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
CorMedix Inc.
Report date February 04, 2026 · Filed February 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 774,749 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 77,156 · Balance 774,749 F1: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,497 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 11,497 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 21:14 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantDirector Stock Option (right to buy) · Derivative | 30,700 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001774807-26-000005 · form4-06242026_090645.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,700 Underlying: Common Stock · 30,700 shares Expires 2036-06-21 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 21:14 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001774807-26-000005 · form4-06242026_090645.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. Read SEC document |
| February 04, 2026 Filed Feb 7, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 77,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-013406 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,749 F1 · price: Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person. Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 27,306 | $7.27 | $198,514.62 |
DisclosureSEC source: 0001213900-26-008478 · ownership.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 697,593 Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 225,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-008478 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,899 F1 · price: These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 17, 2026 Filed Jan 20, 2026 14:28 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 22,665 | $6.78 | $153,668.70 |
DisclosureSEC source: 0001213900-26-005425 · ownership.xml · nonDerivative · entry 3 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,999 Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 14:28 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 29,585 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001213900-26-005425 · ownership.xml · derivative · entry 4 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,245 Underlying: Common Stock · 29,585 shares Expires 2032-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on 5/10/2022. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 14:28 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 29,585 | $3.38 | $99,997.30 |
DisclosureSEC source: 0001213900-26-005425 · ownership.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 521,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The Reporting Person acquired stock through the exercise of options granted on 5/10/2022. The Reporting Person paid the exercise price in cash. No sales of stock were made. Read SEC document |
| January 12, 2026 Filed Jan 20, 2026 14:28 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 17,417 | $7.15 | $124,531.55 |
DisclosureSEC source: 0001213900-26-005425 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 492,079 F1 · date: This transaction is being reported late due to an inadvertent administrative error. Read SEC document |
| December 18, 2025 Filed Dec 20, 2025 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-25-124063 · ownership.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on 01/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| December 18, 2025 Filed Dec 20, 2025 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock | 30,000 | $12.00 | $360,000.00 |
DisclosureSEC source: 0001213900-25-124063 · ownership.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 509,496 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.02, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 18, 2025 Filed Dec 20, 2025 02:30 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 30,000 | $4.43 | $132,900.00 |
DisclosureSEC source: 0001213900-25-124063 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 539,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 22:49 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantDirector Stock Option (right to buy) · Derivative | 38,381 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001774807-25-000005 · form4-10162025_101009.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,381 Underlying: Common Stock · 38,381 shares Expires 2035-10-14 F3 · derivative.exercise_date: The shares subject to the option shall vest in three equal consecutive annual installments on October 14, 2026, October 14, 2027, and October 14, 2028, subject to the Reporting Person's continuous service to the Company. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 22:49 UTC | TALPHERA, INC. TLPH · Entity 7102 | GrantCommon Stock | 6,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001774807-25-000005 · form4-10162025_101009.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,397 F1 · security: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: The restricted stock units shall vest in three equal consecutive annual installments on October 14, 2026, October 14, 2027, and October 14, 2028. Read SEC document |
| September 12, 2025 Filed Sep 13, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 50,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001213900-25-087374 · ownership.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,667 Underlying: Common Stock · 50,000 shares Expires 2034-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on 01/12/2024. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| September 12, 2025 Filed Sep 13, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | SaleCommon Stock | 50,000 | $13.00 | $650,000.00 |
DisclosureSEC source: 0001213900-25-087374 · ownership.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,496 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.82 to $13.27. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 12, 2025 Filed Sep 13, 2025 01:45 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 50,000 | $3.47 | $173,500.00 |
DisclosureSEC source: 0001213900-25-087374 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2025 Filed Sep 13, 2025 01:31 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 21,225 | $11.66 | $247,483.50 |
DisclosureSEC source: 0001213900-25-087371 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,496 F1 · date: This transaction is being reported late due to an inadvertent administrative error. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 11:00 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 59,170 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001213900-25-027598 · ownership.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,830 Underlying: Common Stock · 59,170 shares Expires 2032-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options were granted on 5/10/2022. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 11:00 UTC | CorMedix Inc. CRMD · Entity 5280 | Exercise / conversionCommon Stock | 59,170 | $3.38 | $199,994.60 |
DisclosureSEC source: 0001213900-25-027598 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Reporting Person acquired stock through the exercise of options granted on 5/10/2022. The Reporting Person paid the exercise price in cash. No sales of stock were made. Read SEC document |
| January 17, 2025 Filed Jan 23, 2025 02:11 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 23,977 | $12.17 | $291,800.09 |
DisclosureSEC source: 0001213900-25-005675 · ownership.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,551 Read SEC document |
| January 17, 2025 Filed Jan 23, 2025 02:11 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 187,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-005675 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,528 F1 · price: These shares represent restricted stock units granted on 01/17/2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 00:16 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 17,829 | $11.19 | $199,506.51 |
DisclosureSEC source: 0001213900-25-003534 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,028 Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:22 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 26,982 | $5.17 | $139,496.94 |
DisclosureSEC source: 0000899140-24-000577 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,857 Read SEC document |
| March 13, 2024 Filed Mar 14, 2024 12:45 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 13,561 | $3.74 | $50,718.14 |
DisclosureSEC source: 0000899140-24-000302 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,839 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7250 to $3.7500, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 12, 2024 Filed Jan 18, 2024 01:04 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 266,667 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0000929638-24-000131 · form4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,667 Underlying: Common Stock · 266,667 shares Expires 2034-01-11 F2 · derivative.exercise_date: These options were granted on 01/12/2024. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| January 12, 2024 Filed Jan 18, 2024 01:04 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 13,781 | $3.47 | $47,820.07 |
DisclosureSEC source: 0000929638-24-000131 · form4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,278 Read SEC document |
| January 12, 2024 Filed Jan 18, 2024 01:04 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000929638-24-000131 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,059 F1 · price: These restricted stock units ("RSUs") were granted on 01/12/2024. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These RSUs vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 20:21 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 10,000 | $3.71 | $37,100.00 |
DisclosureSEC source: 0000929638-23-002490 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,726 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7099 to $3.71, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 17, 2023 Filed May 17, 2023 21:35 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 5,000 | $4.58 | $22,900.00 |
DisclosureSEC source: 0000929638-23-001517 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,726 Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:49 UTC Amendment | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 5,000 | $4.58 | $22,900.00 |
DisclosureSEC source: 0000929638-23-001527 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,726 F1 · kind: On May 17, 2023, the reporting person filed a Form 4 which inadvertently included Transaction Code "A". The original Form 4 should have indicated Transaction Code "P". The reporting person has filed this amendment to restate the transaction with the correct Transaction Code. Read SEC document |
| May 10, 2023 Filed May 12, 2023 22:16 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 37,443 | $5.30 | $198,447.90 |
DisclosureSEC source: 0000929638-23-001441 · form4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,726 Read SEC document |
| January 14, 2023 Filed Jan 19, 2023 00:04 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 400,000 | $0.00 Strike: $4.43 | $0.00 |
DisclosureSEC source: 0001213900-23-003557 · ownership.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-01-14 F1 · derivative.exercise_date: These options were granted on 1/14/2023. These options vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:56 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 20,000 | $3.82 | $76,400.00 |
DisclosureSEC source: 0001213900-22-073225 · ownership.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,169 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.77 to $3.85, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 24, 2022 Filed Aug 25, 2022 12:37 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 4,700 | $3.92 | $18,424.00 |
DisclosureSEC source: 0001213900-22-050936 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,169 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 16, 2022 Filed May 17, 2022 12:30 UTC | CorMedix Inc. CRMD · Entity 5280 | PurchaseCommon Stock | 10,000 | $3.38 | $33,800.00 |
DisclosureSEC source: 0001213900-22-027450 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,469 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.36 to $3.40, inclusive. The reporting person undertakes to provide CorMedix Inc., any security holder of CorMedix Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 500,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001213900-22-025973 · doc4.xml · derivative · entry 2 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-05-09 F2 · derivative.exercise_date: These options were granted on 5/10/2022. These options vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:30 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 207,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-025973 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,469 F1 · price: These Restricted Stock Units were granted on 5/10/2022. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest as follows: 50% on the first anniversary of the grant date, 30% on the second anniversary of the grant date, and the remaining 20% on the third anniversary of the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 4,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028164 · doc4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,442 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 1,562 | $3.40 | $5,310.80 |
DisclosureSEC source: 0001209191-22-028164 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,194 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| May 07, 2022 Filed May 10, 2022 22:58 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 4,442 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-028164 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 289,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · derivative · entry 8 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,856 Underlying: Class A Common Stock · 289,856 shares Expires not disclosed F7 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · shares: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F8 · balance_after: Represents a performance-based restricted stock unit grant of 144,928 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 144,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · derivative · entry 7 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,928 Underlying: Class A Common Stock · 144,928 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2023. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 26,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · derivative · entry 6 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,634 Underlying: Class A Common Stock · 26,544 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. F5 · derivative.exercise_date: On March 1, 2021, the reporting person was granted 106,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On March 1, 2021, the reporting person was granted 106,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · derivative · entry 5 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Class A Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 44,444 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 9,331 | $4.45 | $41,522.95 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · nonDerivative · entry 4 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,314 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 26,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · nonDerivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 3,906 | $4.45 | $17,381.70 |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · nonDerivative · entry 2 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,101 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:22 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 11,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016056 · doc4.xml · nonDerivative · entry 1 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. Read SEC document |
| February 27, 2022 Filed Mar 1, 2022 22:12 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 29,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014150 · doc4.xml · derivative · entry 3 Todisco Joseph · CIK 0001774807 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,367 Underlying: Class A Common Stock · 29,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive on share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On February 27, 2020, the reporting person was granted 118,734 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 27, 2020, the reporting person was granted 118,734 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.